In their letter addressed to Clinical Cancer Research, Batalini and colleagues discuss the limitations of our study (1) and we thank them for their comments, which give us the opportunity to clarify some points.

Firstly, the definition of t-MN is chronologic, based on history of cancer treatment with cytotoxic therapy and the 2022 WHO Classification added exposure to PARP inhibitors (PARPi) as a qualifying criterion for t-MN (2). Secondly, our work was descriptive and we did not aim to assess an increased risk of t-MN induced by PARPi as it has already been published (3). That being said, in our center we described an increase of t-MN in ovarian cancer survivors by 52% between 2010–2015 and 2016–2021, as the incidence (normalized to the number of patients with ovarian cancer during the same period) increased from 6,53‰ to 9,91‰. Thirdly, if we agree that...

You do not currently have access to this content.